Skip to Main Content Menu Button

Press Releases

Triplet Therapeutics Presents Preclinical Data for TTX-3360, Announces Equity Pledge at the CHDI Foundation’s 16th Annual HD Therapeutics Conference

April 27, 2021

Triplet Therapeutics to Present at Upcoming Events

March 25, 2021

Triplet Therapeutics Appoints Kathy Biberstein, J.D., and Stephen Webster to its Board of Directors

November 17, 2020

Triplet Therapeutics to Present at Stifel Virtual Healthcare Conference

November 16, 2020

Triplet Therapeutics Completes Enrollment of SHIELD HD Natural History Study of Huntington’s Disease

November 12, 2020

Triplet Therapeutics Announces Participation in Natural History Study of Myotonic Dystrophy Type 1

August 18, 2020

Triplet Therapeutics to Present at Upcoming Events

August 4, 2020

Presentations

CHDI 2022: SHIELD HD – A Natural History Study to Support Clinical and Biomarker Development

In the News

Triplet brings a new strategy to Huntington’s disease

BioCentury
April 28, 2021

Prospects for agents aimed at stopping neuronal loss brighten, driven by new mechanistic understanding

Nature Biotechnology
March 9, 2020

What unifies Huntington’s, spinocerebellar ataxia and myotonic dystrophy? Ness Bermingham’s new startup looks to drug that

Endpoints News
December 17, 2019

Cambridge startup targeting Huntington’s officially debuts after raising $59m

Boston Globe
December 17, 2019

Triplet Therapeutics launches with $59 million to develop antisense therapies for Huntington’s and more

Chemical and Engineering News
December 17, 2019

Atlas, MPM, Partners funnel $49M into a new gene-silencing startup

Boston Business Journal
December 17, 2019

Triplet Therapeutics Unveils $59M to Try Hairpin Fix for Huntington’s

Xconomy
December 17, 2019

Triplet debuts with $59M, therapies for repeat expansion disorders

BioCentury
December 17, 2019

Media contact

Eric Sullivan
Triplet Therapeutics
esullivan@triplettx.com

Stay Connected